This review highlights the current knowledge of epigenetic targets
of anticancer therapy and outlines the current limitations of epigenetic
approaches and the difficulties in defining preventive tools and
strategies. Promising strategies towards achieving the goal of developing
effective epigenetic treatments are discussed, including restoration
or enhancement of sensitivity to other treatment modalities, and
combinations with other agents and new therapeutic areas.
%0 Journal Article
%1 Vogiatzi2007
%A Vogiatzi, Paraskevi
%A Aimola, Pierpaolo
%A Scarano, Maria Irene
%A Claudio, Pier Paolo
%D 2007
%J Drug News Perspect
%K Antineoplastic_Agents,_pharmacology Clinical_Trials_as_Topic Drug_Delivery_Systems Drug_Design Drug_Evaluation,_Preclinical Epigenesis,_Genetic Humans Neoplasms,_drug_therapy/genetics
%N 10
%P 627-633
%R 10.1358/dnp.2007.20.10.1181356
%T Epigenome-derived drugs: recent advances and future perspectives.
%U http://dx.doi.org/10.1358/dnp.2007.20.10.1181356
%V 20
%X This review highlights the current knowledge of epigenetic targets
of anticancer therapy and outlines the current limitations of epigenetic
approaches and the difficulties in defining preventive tools and
strategies. Promising strategies towards achieving the goal of developing
effective epigenetic treatments are discussed, including restoration
or enhancement of sensitivity to other treatment modalities, and
combinations with other agents and new therapeutic areas.
@article{Vogiatzi2007,
abstract = {This review highlights the current knowledge of epigenetic targets
of anticancer therapy and outlines the current limitations of epigenetic
approaches and the difficulties in defining preventive tools and
strategies. Promising strategies towards achieving the goal of developing
effective epigenetic treatments are discussed, including restoration
or enhancement of sensitivity to other treatment modalities, and
combinations with other agents and new therapeutic areas.},
added-at = {2010-01-26T20:35:53.000+0100},
author = {Vogiatzi, Paraskevi and Aimola, Pierpaolo and Scarano, Maria Irene and Claudio, Pier Paolo},
biburl = {https://www.bibsonomy.org/bibtex/21c3e60c02f87b5011beb006c4926361c/denilw},
doi = {10.1358/dnp.2007.20.10.1181356},
institution = {Department of Molecular Biology, Medical Genetics Unit, University
of Siena, Siena, Italy.},
interhash = {4e9cb1fbebe9950eebf709c7a8c7f8b5},
intrahash = {1c3e60c02f87b5011beb006c4926361c},
journal = {Drug News Perspect},
keywords = {Antineoplastic_Agents,_pharmacology Clinical_Trials_as_Topic Drug_Delivery_Systems Drug_Design Drug_Evaluation,_Preclinical Epigenesis,_Genetic Humans Neoplasms,_drug_therapy/genetics},
month = Dec,
number = 10,
owner = {denilw},
pages = {627-633},
pii = {1181356},
pmid = {18301797},
timestamp = {2010-01-26T20:36:04.000+0100},
title = {Epigenome-derived drugs: recent advances and future perspectives.},
url = {http://dx.doi.org/10.1358/dnp.2007.20.10.1181356},
volume = 20,
year = 2007
}